7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      P453 Aspergillus and aspergillosis in patients in an intensive care unit with mechanical ventilation

      abstract

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

           

          Poster session 3, September 23, 2022, 12:30 PM - 1:30 PM

          Invasive Pulmonary Aspergillosis (IPA) is a relevant opportunistic disease among neutropenic patients with hematological diseases. Besides them, studies have been showing that critically ill patients in intensive care units (ICU), mainly those infected by respiratory virus such as SARS-CoV-2 are also at risk to be co-infected by Aspergillus and developing IPA.

          Objectives

          We aimed to evaluate the detection of Aspergillus in tracheal samples from patients in an ICU on mechanical ventilation from a tertiary hospital from Southern Brazil, and its relationship with their outcome.

          Methods

          All samples of tracheal aspirate (TA) from patients admitted to the ICU and in mechanical ventilation from July 2020 to June 2021 were included in the study. We performed three different tests to detect Aspergillus spp.: (1) mycological culture in Sabouraud Agar Dextrose, with macro and microscopy evaluation of the colonies to the identification of Aspergillus section; (2) lateral flow assay for the detection of Aspergillus Galactomannan (GM) performed with the cube reader (IMMY® Diagnostics, OK, USA), using a cut-off of ≥4 (nm/ml); (3) quantitative polymerase chain reaction (qPCR) with GoTaq® Probe qPCR (Promega, Wisconsin, EUA) to amplify the small subunit ribosomal RNA target using the forward (3’ TTGGTGGAGTGATTTGTCTGCT 5’), and reverse (5’ TCTAAGGGCATCACAGACCTG 3’) primers, and the probe (3’ TCGGCCCTTAAATAGCCCGGTCCGC 5). Samples presenting the cycle threshold (CT) <40 were considered positive. DNA obtained from an Aspergillus isolate was used as positive control, and DNA-free water as negative control. Probable aspergillosis was defined in those cases that presented positive results to, at least, two of these tests.

          Results

          A total of 34 patients were included in the study. Causes of ICU admissions were aids complications ( n = 11), COVID-19 ( n = 9), severe acute kidney disease ( n = 6), tuberculosis ( n = 1), and other reasons, including post-surgery, septic shock, severe acute respiratory syndrome, and cardiac problems ( n = 6). Aspergillus spp. was isolated in culture of the TA in 50% of the patients (17/34), being 12 Aspergillus section Fumigati, three Aspergillus section Flavi, and two Aspergillus section Nigri. TA from eight patients were positive for GM, and five patients had a positive result in the qPCR assay. Probable aspergillosis was confirmed in 20.6% (7/34), being three patients positive in culture and GM, and three in culture and qPCR. One patient was positive in the three tests. COVID-19-associated aspergillosis (CAPA) corresponded to two of these seven cases. The outcome was death in 13/34 patients, 4 of them (31%) had probable aspergillosis. The other three patients, alive, diagnosed with probable aspergillosis, were treated with amphotericin B, desoxicolate plus itraconazole, and survived. The mortality rate was 57.1% (4/7) and 33.3% (9/27) in the group with and without probable aspergillosis, respectively.

          Conclusion

          These partial results suggest that aspergillosis can have an important impact in critically ill patients in the intensive care unit of our hospital.

          Related collections

          Author and article information

          Contributors
          Journal
          Med Mycol
          Med Mycol
          mmy
          Medical Mycology
          Oxford University Press
          1369-3786
          1460-2709
          September 2022
          20 September 2022
          20 September 2022
          : 60
          : Suppl 1
          : myac072P453
          Affiliations
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          Medical Microbiology Research Center (NUPEMM) , Federal University of Rio Grande, Rio Grande, Brazil
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          University Hospital Dr. Miguel Riet Correa Jr. (HU-FURG/Ebserh) , Federal University of Rio Grande, Rio Grande, Brazil
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          National Institute of Health , Dr. Ricardo Jorge, Lisbon, Portugal
          Post-Graduate Program in Pathology , Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, Brazil
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          Laboratory of Medical Mycology , Faculty of Medicine, Federal University of Rio Grande, Rio Grande, Brazil
          Post-graduate Program in Health Sciences , Federal University of Rio Grande, Rio Grande, Brazil
          Article
          myac072.P453
          10.1093/mmy/myac072.P453
          9494500
          051a83e2-e07c-4eac-b915-842bef46ab31
          © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@ 123456oup.com

          History
          Categories
          Oral Presentations
          AcademicSubjects/MED00010
          AcademicSubjects/SCI00960

          Infectious disease & Microbiology
          Infectious disease & Microbiology

          Comments

          Comment on this article